Skin Substitutes Grafts/Cellular and Tissue-Based Products (Injections and/or Applications) | UHC Coverage Update

TL;DR: UnitedHealthcare modified its Medicare Advantage coverage policy for skin substitutes grafts and cellular and tissue-based products (CTP), effective February 2, 2026. Here's what billing teams need to do.

This update to UnitedHealthcare's skin substitutes CTP injection and application policy touches over 300 HCPCS codes — from A2001 through the Q4100-series — and reinforces a compliance structure built around Local Coverage Determinations (LCDs) and Local Coverage Articles (LCAs). The policy code is skin-substitues-ctp-injection-application. If your practice bills for wound care, musculoskeletal injections, or amniotic and placental derived products, this change deserves your immediate attention.

Quick-Reference Table

UnitedHealthcare Skin Substitutes Coverage Criteria and Medical Necessity Requirements 2026

The real issue here is jurisdictional complexity. UnitedHealthcare's skin substitutes coverage policy does not rely on a National Coverage Determination (NCD) — because no NCD exists for either skin substitutes grafts/CTPs or amniotic and placental derived product injections. Instead, coverage runs through LCDs and LCAs at the Medicare Administrative Contractor (MAC) level.

That means coverage for a given code depends entirely on where your patient receives care. Your MAC's local coverage determination controls what's covered, what documentation is required, and what constitutes medical necessity for that claim. UnitedHealthcare's Medicare Advantage policy requires compliance with these LCDs and LCAs where they exist — and LCDs/LCAs now exist for all states.

For states or territories without an applicable LCD/LCA — or for indications not listed in existing LCDs/LCAs (other than breast reconstruction) — UnitedHealthcare directs you to its Commercial Medical Policy titled Skin and Soft Tissue Substitutes. Breast reconstructive procedures have their own separate coverage guidelines. Make sure your billing team knows which pathway applies before submitting a claim.

This policy does not specify prior authorization requirements for skin substitute products. PA requirements under UnitedHealthcare Medicare Advantage vary by plan, state, and MAC jurisdiction and are not addressed in this policy document. Check UHC's prior authorization tool and your MAC's LCD directly before scheduling any procedure. A claim denial after a costly graft application is a billing failure you can prevent upstream. If you're unsure how PA applies to your specific plan mix, talk to your compliance officer before the procedure date.

UnitedHealthcare Skin Substitutes Coverage Indications at a Glance

UnitedHealthcare Skin Substitutes Billing Guidelines and Action Items 2026

The skin-substitues-ctp-injection-application policy in the UnitedHealthcare system is not a set-it-and-forget-it policy. The LCD/LCA structure means your billing team needs to track multiple variables simultaneously. Here's exactly what to do.

If your practice has significant volume in wound care or musculoskeletal injections, loop in your compliance officer before your next billing cycle. The LCD/LCA structure creates real exposure if your team is applying the wrong jurisdiction's criteria to a claim.

CPT, HCPCS, and ICD-10 Codes for Skin Substitutes Under skin-substitues-ctp-injection-application

This policy governs 302 HCPCS codes total. Below is the full list from the policy data. Every one of these codes is subject to the LCD/LCA compliance requirement described above.

Covered HCPCS Codes — When LCD/LCA Criteria Are Met

The full policy lists 302 HCPCS codes total. The 222 additional codes follow the same A2xxx and Q4xxx series structure. Access the complete list at the UHC policy source.

Deleted / Non-Billable Codes

A Note on the Billing Guidelines for Injectable vs. Sheet-Form Products

Your billing team needs to distinguish between injectable formulations and sheet-form grafts. Products like Q4112 (Cymetra, injectable, 1 cc), Q4114 (Integra flowable wound matrix, injectable, 1 cc), Q4139 (AmnioMatrix or BioDMatrix, injectable, 1 cc), Q4145 (EpiFix, injectable, 1 mg), and Q4155 (Neox Flo or Clarix Flo, 1 mg) bill by volume or weight — not by square centimeter. Sheet-form products bill per sq cm. The unit of measure on the claim must match the HCPCS descriptor exactly. A unit-of-measure mismatch is an automatic denial, and it's one of the most common errors in skin substitutes billing.

Reimbursement for these products varies by MAC and is not addressed in this policy. Your MAC's fee schedule and reimbursement methodology — not the UHC policy document — determine what a product pays. Check your MAC's published fee schedule directly and confirm financial viability with your revenue cycle team before committing to a product mix.